Shuttle Pharmaceuticals Holdings, Inc. SHPH
November 21, 2025, we acquired substantially all of the assets and liabilities of Molecule.ai, a pharmaceutical software company
building an artificial intelligence ("AI") driven platform for molecular discovery and early-stage drug development. By combining modern AI techniques with structured scientific workflows, the Molecule.ai
platform (hereafter, "Molecule.ai" or the "platform") helps researchers explore the chemical space more efficiently,
evaluate molecular ideas with greater clarity and make more informed decisions during the earliest stages of drug development. The platform
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| R&D | $4.1M | $3.6M | $3.5M | $1.0M | $1.0M | — |
| SG&A | $5.7M | $1.4M | $1.0M | $473.7K | $36.5K | — |
| Total operating expenses | $11.9M | $7.7M | $5.9M | $2.3M | $1.7M | — |
| Operating income | -$11.9M | -$7.7M | -$5.9M | -$2.3M | -$1.7M | — |
| Interest expense | — | $100.0K | $100.0K | — | — | — |
| Pre-tax income | — | — | -$6.6M | -$5.0M | -$1.2M | — |
| Net income | -$11.7M | -$9.1M | -$6.6M | -$5.0M | -$1.2M | — |
| EPS, basic | -7.16 | -79.65 | -3.53 | -5.04 | -0.12 | — |
| EPS, diluted | -7.16 | -82.60 | -3.53 | -5.04 | — | — |
| Shares, diluted (wtd. avg.) | 1.6M | 115,493 | 1.9M | 1.3M | 9.3M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $334.0K | $1.9M | $2.6M | $8.4M | $504.7K | — |
| Short-term investments | — | — | $2.9M | — | — | — |
| Total current assets | $502.9K | $2.2M | $5.6M | $8.6M | $509.6K | — |
| Property, plant and equipment | $17.3K | $19.4K | $24.8K | $12.6K | $18.6K | — |
| Other intangibles | $9.8M | — | — | — | — | — |
| Total assets | $10.5M | $2.5M | $6.0M | $8.7M | $651.6K | — |
| Accounts payable | $1.5M | $596.6K | — | — | — | — |
| Total current liabilities | $8.0M | $1.5M | $1.0M | $975.7K | $2.2M | — |
| Long-term debt | — | — | — | — | $91.0K | — |
| Total liabilities | $8.2M | $1.8M | $1.9M | $975.7K | $2.3M | — |
| Retained earnings | -$46.3M | -$34.6M | -$25.4M | -$18.8M | -$13.8M | — |
| Total equity | $2.3M | $709.2K | $4.1M | $7.7M | -$1.8M | -$1.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$9.5M | -$7.3M | -$5.6M | -$2.7M | -$300.3K | — |
| Depreciation and amortisation | — | $5.5K | $6.8K | $6.0K | $6.2K | — |
| Stock-based compensation | $933.0K | $259.7K | $182.0K | $237.5K | $910.1K | — |
| Capital expenditure | — | — | $19.0K | — | — | — |
| Investing cash flow | -$3.1M | $2.9M | -$2.8M | — | — | — |
| Financing cash flow | $11.0M | $3.8M | $2.6M | $10.6M | $687.9K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-014131.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Net income | — | -$1.2M | -$5.0M | -$6.6M | -$9.1M | -$11.7M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed Item 1.01
- Acquisition or disposal completed Item 2.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |